FOXM1 Variant Contributes to Gefitinib Resistance via Activating Wnt/β-Catenin Signal Pathway in Patients with Non-Small Cell Lung Cancer.

Shaoxing GuanXi ChenYouhao ChenWen XieHeng LiangXia ZhuYunpeng YangWenfeng FangYan HuangHongyun ZhaoWei ZhuangShu LiuMin HuangXueding WangLi Zhang

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

These findings characterized rs3742076_G as a gain-of-function polymorphism in mediating gefitinib resistance and tumor aggressiveness, and highlighted the variant as a predictive biomarker in guiding gefitinib treatment.

Keyphrases

small cell lung cancer
epidermal growth factor receptor
cell proliferation
stem cells
signaling pathway
epithelial mesenchymal transition
tyrosine kinase
smoking cessation